Cyanide: critical issues in diagnosis and treatment
Tóm tắt
The concern of a terrorist attack using cyanide, as well as the gradual awareness of cyanide poisoning in fire victims, has resulted in a renewed interest in the diagnosis and treatment of cyanide poisoning. The formerly academic presentation of cyanide poisoning must be replaced by more useful knowledge, which will allow emergency physicians and rescue workers to strongly suspect cyanide poisoning at the scene. Human cyanide poisonings may result from exposure to cyanide, its salts, or cyanogenic compounds, while residential fires are the most common condition of exposure. In fire victims, recognition of the cyanide toxidrome has been hampered by the short half-life in blood and poor stability of cyanide. In contrast, carboxyhemoglobin, as a marker of carbon monoxide poisoning, is easily measured and long-lasting. No evidence supports the assumption of the arbitrary fixed lethal thresholds of 50% for carboxyhemoglobin, and 3 mg/L for cyanide, in fire victims. Preliminary data, drawn when comparing pure carbon monoxide and pure cyanide poisonings, suggest that a cyanide toxidrome can be defined considering signs and symptoms induced by cyanide and carbon monoxide, respectively. Prospective studies in fire victims may provide value in clarifying signs and symptoms related to both toxicants. Cyanide can induce a lifethreatening poisoning from which a full recovery is possible. A number of experimentally efficient antidotes to cyanide exist, whose clinical use has been hampered due to serious side effects. The availability of potentially safer antidotes unveils the possibility of their value as first-line treatment, even in a complex clinical situation, where diagnosis is rapid and presumptive.
Từ khóa
Tài liệu tham khảo
Hall AH, 1987, Clinical and experimental toxicology of cyanides, 312
Borron SW, 1996, Arhiv za Higijenu Rada i Toksikologiju, 47, 307
Curry SC, 2005, Critical care toxicology. Diagnosis and management of the critically poisoned patient, 987
Bryson D., 1987, Clinical and experimental toxicology of cyanides, 348
Ballantyne B, 1987, Clinical and experimental toxicology of cyanides, 217
Targosz D, 1999, Przeglad Lekarski, 56, 415
Akkose S, 2005, Clin Toxicol, 43, 105
Moureu H, 1957, Arch Malad Prof (Paris), 18, 116
Gourlain H, 1998, Presse Méd, 28, 163
Haldane J, 1935, Respiration
Meredith T, 1992, IPCS/CEC evaluation of antidotes series, 1
Barois A, 1979, Rev Pratic, 29, 1211
Blettery B, 1983, Ann Méd Int (Paris), 134, 99
Meigs JW, 1952, AMA Arch Ind Hyg Occup Med, 6, 344
Goulon M, 1969, Ann Méd Inter (Paris), 120, 335
Bogusz M, 1972, Eur J Toxicol Hyg Environ, 5, 306
Leikin JB, 1980, Vet Hum Toxicol, 30, 40
Gracey DR, 1974, Heart Lung, 3, 817
Lebby TI, 1989, Vet Hum Toxicol, 31, 138
Bismuth C, 1984, Presse Méd, 13, 2493
Evans CL, 1964, Br J Pharmacol, 23, 455
Fortin JL, 2004, JEMS: J Emerg Med Serv, 29, S18
Hall AH, 1989, J Toxicol Clin Exp, 9, 3
Rachinger J, 2002, Am J Neuroradiol, 23, 1398